血小板活化因子受体拮抗剂治疗缺血性卒中的中国专家共识

2020-02-12 中国卒中学会 中国神经免疫学和神经病学杂志.2020.27(1):1-6.

血小板活化因子(PAF)于20世纪70年代初由法国免疫学家Jacques Benveniste发现。其命名起源于它最初被发现的血小板聚集功能,但目前已发现其具有广泛的生理和病理效应。PAF受体(PAF

中文标题:

血小板活化因子受体拮抗剂治疗缺血性卒中的中国专家共识

发布机构:

中国卒中学会

发布日期:

2020-02-12

简要介绍:

血小板活化因子(PAF)于20世纪70年代初由法国免疫学家Jacques Benveniste发现。其命名起源于它最初被发现的血小板聚集功能,但目前已发现其具有广泛的生理和病理效应。PAF受体(PAFR)拮抗剂有着不同于既往抗血小板药物的作用机制,具有抗炎、神经保护等多种效应。PAFR拮抗剂在中国已被广泛应用于老年性血液循环障碍疾病的治疗。近年来,越来越多的证据提示PAFR拮抗剂是缺血性脑血管疾病有效的新治疗措施。

相关资料下载:
[AttachmentFileName(sort=1, fileName=)] GetToolGuiderByIdResponse(projectId=1, id=f26491c0018e52fa, title=血小板活化因子受体拮抗剂治疗缺血性卒中的中国专家共识, enTitle=, guiderFrom=中国神经免疫学和神经病学杂志.2020.27(1):1-6., authorId=0, author=, summary=血小板活化因子(PAF)于20世纪70年代初由法国免疫学家Jacques Benveniste发现。其命名起源于它最初被发现的血小板聚集功能,但目前已发现其具有广泛的生理和病理效应。PAF受体(PAF, cover=https://medsci-open-files.oss-cn-shanghai.aliyuncs.com/脑子_1583762585000.png, journalId=0, articlesId=null, associationId=1192, associationName=中国卒中学会, associationIntro=中国卒中学会, copyright=0, guiderPublishedTime=Wed Feb 12 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>血小板活化因子(PAF)于20世纪70年代初由法国免疫学家Jacques Benveniste发现。其命名起源于它最初被发现的血小板聚集功能,但目前已发现其具有广泛的生理和病理效应。PAF受体(PAFR)拮抗剂有着不同于既往抗血小板药物的作用机制,具有抗炎、神经保护等多种效应。PAFR拮抗剂在中国已被广泛应用于老年性血液循环障碍疾病的治疗。近年来,越来越多的证据提示PAFR拮抗剂是缺血性脑血管疾病有效的新治疗措施。</p> </div> </div> </div>, tagList=[TagDto(tagId=517, tagName=血小板), TagDto(tagId=320, tagName=缺血性卒中)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=320, guiderKeyword=缺血性卒中, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4054, appHits=102, showAppHits=0, pcHits=1094, showPcHits=3932, likes=5, shares=6, comments=3, approvalStatus=1, publishedTime=Tue Mar 10 17:38:38 CST 2020, publishedTimeString=2020-02-12, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 09 22:03:12 CST 2020, updatedBy=1, updatedName=小M, updatedTime=Sat Jan 06 14:57:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=)])
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=898196, encodeId=a26689819633, content=学习一下,非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=wEOMeZQa2GWaAgc0wCNk5g&s=100&t=1586593188, createdBy=4a485322413, createdName=阿普唑仑, createdTime=Tue Nov 10 10:05:55 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880644, encodeId=9d5888064495, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/1IAgiaWNJ5zFKEL0BJP1eUeP64r1N39eQeSrqjiaMqNccGbpLia00lKuN1NWjV40oQgfw01I0WBj34BrFl5ARgDPw/132, createdBy=d7205268185, createdName=太空旅客, createdTime=Sat Aug 29 19:33:03 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2020-11-10 阿普唑仑

    学习一下,非常有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=898196, encodeId=a26689819633, content=学习一下,非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=wEOMeZQa2GWaAgc0wCNk5g&s=100&t=1586593188, createdBy=4a485322413, createdName=阿普唑仑, createdTime=Tue Nov 10 10:05:55 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880644, encodeId=9d5888064495, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/1IAgiaWNJ5zFKEL0BJP1eUeP64r1N39eQeSrqjiaMqNccGbpLia00lKuN1NWjV40oQgfw01I0WBj34BrFl5ARgDPw/132, createdBy=d7205268185, createdName=太空旅客, createdTime=Sat Aug 29 19:33:03 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2020-08-29 太空旅客

    学习

    0